Clinical Trial Update: Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports results from Phase 2 and Phase 3 studies evaluating reslizumab for eosinophilic esophagitis in children aged 5 to 18, with th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• reslizumab (reslizumab)

Snippet

Sponsor: Ception Therapeutics | Conditions: Eosinophilic Esophagitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-09-02